Form 4: Director Suketu Upadhyay Increases Vertex Equity Stake

Vertex Pharmaceuticals director Suketu Upadhyay acquired 80.508 deferred stock units as part of board compensation.

Summary

• Director Suketu Upadhyay was granted 80.508 deferred stock units (DSUs) on April 15, 2026.
• Each DSU represents a right to receive one share of common stock.
• The transaction increases the director's total beneficial ownership to 2,799.156 units.
• The units are valued at $442.50 per unit based on the filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the deferred stock units is subject to market volatility of Vertex Pharmaceuticals common stock.

Future Outlook

The deferred stock units will be settled in common stock upon the director's termination of service, a change of control, or in the event of disability or death.

Management Comments

• None provided.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the biotechnology sector to ensure directors remain incentivized to oversee long-term growth.

Comparison to Industry Standards

• The use of deferred stock units for director compensation is consistent with standard practices among large-cap pharmaceutical companies like Amgen, Gilead, and Regeneron.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event for a board member.

Next Steps

• The units will remain held until the occurrence of a triggering event such as termination of service or change of control.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Director Compensation, Equity Ownership